Pyridothienopyridazinone derivatives as mGluR1 antagonists
US7687501B2 · kind B2 · utility
2Cited by
3References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2006 |
| Grant date | Mar 30, 2010 |
| Priority date | — |
| Expiry date | Aug 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.